Lumito AB publishes Quarterly Report 1, 2024
Financial overview of the first quarter January 1 to March 31, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -7 113 (-7 245). Earnings per share before and after dilution amounted to SEK -0,03 (-0,04). Cash flow from operating activities after changes in working capital amounted to TSEK -7 180 […]
Lumito AB publishes Quarterly Report 4, 2023
Financial overviewFourth quarterOctober 1 – December 31, 2023 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -5 777 (-6 612). Earnings per share before and after dilution amounted to SEK -0,03 (-0,03). Cash flow from operating activities after changes in working capital amounted to TSEK -5 480 (-5 153). Full […]
Research group at the Tyndall National Institute got an article published on the use of up-converting nanoparticles
A research group at the Tyndall National Institute in Cork, Ireland, got an article published in Biomedical Optics Express titled "High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles". The research study uses Lumito's technology with up-converting nanoparticles (UCNPs). The article examines the use of UCNPs to distinguish different levels of HER2 […]
Conversion of paid subscribed units (BTU) and first day of trading with warrants of series TO5 and TO6
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumitos issue of warrants is fully subscribed multiple times
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Last day of trading with unit rights in Lumito
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
The subscription period in Lumito’s issue of warrants begins today
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumito publishes prospectus in connection with issue of warrants
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumito notifies changes to terms for the issue of free-of-charge warrants
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumito attends the Digital Pathology & AI Congress in London
On December 7–8, Lumito will exhibit with a booth at the annual Digital Pathology & AI Congress in London. The presence is part of the company's branding work within the company's primary target group ahead of the upcoming launch of SCIZYS. – It is important for us to build trust around our brand and product. […]